AR060284A1 - Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida - Google Patents

Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida

Info

Publication number
AR060284A1
AR060284A1 ARP070101414A ARP070101414A AR060284A1 AR 060284 A1 AR060284 A1 AR 060284A1 AR P070101414 A ARP070101414 A AR P070101414A AR P070101414 A ARP070101414 A AR P070101414A AR 060284 A1 AR060284 A1 AR 060284A1
Authority
AR
Argentina
Prior art keywords
diazepino
acetamide
oxo
amino
methyl
Prior art date
Application number
ARP070101414A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR060284A1 publication Critical patent/AR060284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a terapias de combinacion de (2R,Z)-2-amino-2-ciclohexil-N-(5-(1-metil-1H-pirazol-4-il)-1-oxo-2,6-dihidro-1H[1,2]diazepino[4,5,6-cd]indol-8-il)acetamida de formula (1), una sal o solvato farmacéuticamente aceptable de la misma, o una mezcla de los mismos, en combinacion con un agente anticancerígeno o terapia de radiacion.
ARP070101414A 2006-04-04 2007-04-03 Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida AR060284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78927606P 2006-04-04 2006-04-04

Publications (1)

Publication Number Publication Date
AR060284A1 true AR060284A1 (es) 2008-06-04

Family

ID=38421777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101414A AR060284A1 (es) 2006-04-04 2007-04-03 Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida

Country Status (14)

Country Link
US (1) US20090312280A1 (es)
EP (1) EP2007375A1 (es)
JP (1) JP2007277240A (es)
KR (1) KR20080100838A (es)
CN (1) CN101415417A (es)
AR (1) AR060284A1 (es)
AU (1) AU2007232279B2 (es)
BR (1) BRPI0709731A2 (es)
CA (1) CA2648371A1 (es)
IL (1) IL194340A0 (es)
MX (1) MX2008012791A (es)
RU (1) RU2409361C2 (es)
TW (1) TW200806301A (es)
WO (1) WO2007113671A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113436A1 (ja) * 2008-03-14 2009-09-17 国立大学法人千葉大学 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法
RU2482855C2 (ru) * 2008-03-27 2013-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, включающее производное цитидина и карбоплатин
BRPI1013920A2 (pt) * 2009-04-11 2016-04-05 Array Biopharma Inc inibidores de ponto de checagem de quinase 1 para potencializar agentes de danificação de dna
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
RU2627841C2 (ru) 2010-11-16 2017-08-14 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
CN103703004B (zh) 2011-12-31 2016-06-29 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
US9328111B2 (en) 2011-12-31 2016-05-03 Beigene Ltd. Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1585749T1 (sl) * 2003-01-09 2008-10-31 Pfizer Derivati diazepinoindola kot inhibitorji kinaze

Also Published As

Publication number Publication date
AU2007232279B2 (en) 2010-05-06
CN101415417A (zh) 2009-04-22
CA2648371A1 (en) 2007-10-11
WO2007113671A1 (en) 2007-10-11
JP2007277240A (ja) 2007-10-25
US20090312280A1 (en) 2009-12-17
AU2007232279A1 (en) 2007-10-11
EP2007375A1 (en) 2008-12-31
RU2409361C2 (ru) 2011-01-20
BRPI0709731A2 (pt) 2011-07-26
TW200806301A (en) 2008-02-01
IL194340A0 (en) 2009-08-03
KR20080100838A (ko) 2008-11-19
RU2008139406A (ru) 2010-04-10
MX2008012791A (es) 2008-10-15

Similar Documents

Publication Publication Date Title
AR060284A1 (es) Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
CL2008002139A1 (es) Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer.
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
MY157218A (en) Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
CL2011003046A1 (es) Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).
WO2008030617A3 (en) Cancer therapy with cantharidin and cantharidin analogs
CR9846A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
CU20120150A7 (es) Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina-sustituida
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AR082692A1 (es) Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal